Eli Lilly and Merck KGaA supply cetuximab for Adlai Nortye cancer trial

Adlai Nortye Group Ltd announced a clinical trial collaboration and supply agreement with Eli Lilly and Company and Merck KGaA, Darmstadt, Germany. The agreement is designed to test Adlai Nortye's experimental cancer drug AN4035 alongside the antibody cetuximab. Eli Lilly and Company will supply cetuximab at no cost to trial sites in the United States, while Merck KGaA will provide it for sites in Australia and China.

The collaboration supports the ongoing global Phase I trial of AN4035, which is described as a first-in-class investigational pan-RAS(ON) inhibitor-based antibody-drug conjugate. The involvement of Eli Lilly and Company and Merck KGaA is limited to supplying cetuximab free of charge, as Adlai Nortye remains the sole sponsor of the trial.